



Exhibiting EXPO 2025
Osaka Kansai

Company Name: Pharma Foods International Co., Ltd.
Representative: Representative Director, Mujo Kim
Stock Exchange Market: Tokyo Prime (2929)
Head Office: 1-49 Goryo-Ohara, Nishikyo-ku, Kyoto 615-8245
Contact Number: +81-75-394-8600

News Release

February 12, 2025

The establishment of World's first "CADASIL Drug Discovery Research Department" in collaboration with National Cerebral and Cardiovascular Center

Pharma Foods International Co., Ltd. (Hereinafter: PFI) and National Cerebral and Cardiovascular Center (Head Office: Suita City, Osaka Prefecture, Chairperson: Kinya Otsu, Hereinafter: NCVC) will jointly establish the world's first **"CADASIL Drug Discovery Research Department"** with the aim of developing a therapeutic agent for the treatment of **CADASIL**, a designated intractable disease.

With the mission of "contributing through pharmaceutical and dietary research," the PFI Group is committed to creating new value in the healthcare field through innovative research and development.

In the area of pharmaceuticals, Mitsubishi Tanabe Pharma Corporation is currently conducting Phase 1 clinical trials for antibodies developed utilizing our proprietary "Aladdin Technology," a chicken-derived antibody production technology, with the aim of developing therapeutic agents for autoimmune diseases.

CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is one of the government-designated intractable diseases (designated intractable disease 124) with no fundamental cure in the world and a very high unmet medical need. The disease is believed to be caused by mutation of the NOTCH3 gene; abnormalities in the NOTCH3 gene damage blood vessels in the brain, resulting in severe symptoms such as migraine headaches, cerebral infarction, cerebral hemorrhage, and dementia.

NCVC is a national center for highly specialized medical research under the jurisdiction of the Ministry of Health, Labour and Welfare. It is recognized as one of the premier institutions for research and treatment of cardiovascular diseases in Japan.

Our partner in this joint research, Dr. Masafumi Ihara, General Manager of the Department of Neurology, is a foremost expert in the field of CADASIL research and treatment. Dr. Ihara has recently been conducting investigator-initiated clinical trials (Phase 2) on adrenomedullin peptide, a new drug candidate for CADASIL, which is expected to be effective. Dr. Ihara is also actively involved in the establishment of Japan's first outpatient hospital specializing in CADASIL and the CADASIL Patients Association.

Based on our long-standing years of extensive peptide research and development, PFI will advance the development of CADASIL therapeutics through this joint research and contribute to the health of people around the world by delivering effective therapeutics to patients suffering from intractable diseases.



NCVC for Advanced Medical Specialties was established in 1977 to ensure the health of the public in concert with national medical policy, which consists three institutions: a hospital, a research institute, and an open innovation center.

Website: <https://www.ncvc.go.jp/english/>

